Clinical Trial Update: A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating elranatamab in relapsed or refractory multiple myeloma; results are posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Pfizer | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2024-07-30